Thousands of women who received textured breast implants are now pursuing legal claims against Allergan after the company’s Biocell textured implants were linked to a rare but serious cancer called breast implant-associated anaplastic large cell lymphoma, or BIA-ALCL. As of May 2025, there are 1,425 plaintiffs with pending cases in the Allergan Biocell multidistrict litigation (MDL No. 2921) in the U.S. District Court for the District of New Jersey, with the first bellwether trial scheduled for June 15, 2026.
No settlement has been reached, and Allergan has not yet tendered a formal settlement offer. The FDA requested Allergan recall all Biocell textured breast implants and tissue expanders in July 2019, after tracking a mounting number of BIA-ALCL cases tied overwhelmingly to the company’s products. Since then, more than 1,200 lawsuits have been filed. Plaintiffs allege Allergan failed to properly warn women about the cancer risk, leaving them to face painful diagnoses, explant surgeries, and in some cases, death. This article covers the medical background of BIA-ALCL, the current state of the litigation, what the bellwether trials could mean for plaintiffs, and what women with textured implants should know right now.
Table of Contents
- What Is BIA-ALCL and Why Is It at the Center of Textured Breast Implant Cancer Lawsuits?
- The Allergan Biocell Recall and How the MDL Took Shape
- Bellwether Trials Set for 2026 Could Define the Litigation’s Future
- What Damages Are Plaintiffs Seeking in the Allergan Breast Implant Lawsuit?
- Settlement Prospects and Why Resolution Remains Uncertain
- New Research Links BRCA Mutations to Higher BIA-ALCL Risk
- What Comes Next for Textured Breast Implant Litigation
- Conclusion
- Frequently Asked Questions
What Is BIA-ALCL and Why Is It at the Center of Textured Breast Implant Cancer Lawsuits?
BIA-ALCL is a rare form of T-cell lymphoma that develops in the scar tissue and fluid surrounding a breast implant. It is not breast cancer in the traditional sense — it is a cancer of the immune system. The World Health Organization officially classified BIA-ALCL as a distinct disease in 2016, giving it formal recognition after years of case reports and growing concern among surgeons and oncologists. The median time from implant placement to BIA-ALCL diagnosis is nine years, though cases have been documented anywhere from one to 22 years after surgery. What makes the lawsuits so pointed is the concentration of risk.
According to FDA data current as of June 30, 2024, the agency has tracked 1,380 cases of BIA-ALCL since 2011, with 64 deaths worldwide. Of those reported cases, 86 percent were associated with allergan textured implants specifically — not textured implants in general, but one manufacturer’s product line. That statistic is central to the plaintiffs’ argument that Allergan knew or should have known its Biocell surface texture posed a disproportionate danger. The lifetime risk estimates vary widely, from 1 in 3,817 to 1 in 30,000 women with textured breast implants. That range reflects the difficulty of tracking a disease that can take over a decade to manifest and that many physicians were not screening for until recently. For the women who do develop BIA-ALCL, the consequences can be severe — requiring implant removal, chemotherapy, and in advanced cases, treatment regimens similar to those used for aggressive lymphomas.
The Allergan Biocell Recall and How the MDL Took Shape
The FDA’s July 2019 recall request was not a routine action. Allergan initially resisted pulling the product from the market even as regulators in France, Canada, and other countries had already banned or restricted textured implants. When the FDA finally made the formal request, it cited the disproportionate number of BIA-ALCL cases linked to Biocell implants compared to other manufacturers’ devices. The recall covered all Biocell textured breast implants and tissue expanders still on the market or sitting unused in surgical facilities. Lawsuits followed quickly, and the Judicial Panel on Multidistrict Litigation consolidated them into mdl No. 2921 in the District of New Jersey.
As of May 2025, the case count stands at 1,425 plaintiffs, though the pace of new filings has slowed — only 200 new cases were added in the eight months prior to that date. That slowdown may reflect the natural maturation of the litigation rather than a lack of affected women. Many potential plaintiffs may not yet know they have grounds for a claim, particularly those who have not experienced symptoms or who were not informed about the recall by their surgeons. However, women considering filing should understand that the window for legal action is not unlimited. Statutes of limitations vary by state, and the clock typically starts running from the date of diagnosis or the date the plaintiff knew or should have known about the link between their implant and their condition. Women who received textured implants from any manufacturer — not only Allergan — and who have experienced symptoms like persistent swelling, pain, or lumps near the implant site should consult both a physician and an attorney sooner rather than later.
Bellwether Trials Set for 2026 Could Define the Litigation’s Future
Bellwether trials serve as test cases in multidistrict litigation. They allow both sides to see how juries respond to the evidence, the testimony, and the legal arguments before hundreds or thousands of similar cases go to trial. In the Allergan Biocell MDL, fact discovery in all six bellwether cases was scheduled to be completed by February 6, 2026, setting the stage for the first trial. That first bellwether trial is set for June 15, 2026, and will involve a surgical explant case — meaning the plaintiff underwent surgery to remove their textured implants. It has not yet been decided whether this will be a single-plaintiff or multi-plaintiff trial, a distinction that could significantly affect how the jury weighs the evidence. A second bellwether trial is scheduled for October 19, 2026.
Pretrial disclosures, including deposition designations and trial exhibit lists, must be filed by April 22, 2026. Five additional cases are expected to be scheduled for bellwether trials beyond the first two. The outcomes of these trials will carry enormous weight. If plaintiffs win substantial verdicts, Allergan will face intense pressure to negotiate a global settlement rather than defend hundreds of individual cases. If Allergan prevails, plaintiffs’ attorneys may need to recalibrate their strategies. In mass tort litigation, the bellwether phase is often where the real shape of the settlement begins to emerge — not in mediation rooms, but in courtrooms where juries put dollar figures on harm.
What Damages Are Plaintiffs Seeking in the Allergan Breast Implant Lawsuit?
Plaintiffs in the Biocell MDL are alleging a range of damages that reflect both the financial and personal toll of a BIA-ALCL diagnosis. The claimed damages include costs of diagnosis and treatment, explant surgery, reconstructive surgery, lost wages, pain and suffering, and emotional distress. For a woman who received breast implants after a mastectomy — a common scenario in breast cancer reconstruction — the prospect of undergoing yet another surgery to remove a product that was supposed to help her recover is particularly devastating. The core legal argument is a failure-to-warn claim: plaintiffs contend that Allergan knew or should have known about the elevated BIA-ALCL risk associated with its Biocell texture and failed to adequately disclose that risk to patients and their surgeons. This is distinct from a manufacturing defect claim.
Plaintiffs are not necessarily arguing the implants were built wrong — they are arguing that the inherent risk of the product’s design was concealed or minimized. There is an important tradeoff for potential plaintiffs to understand. Joining the MDL offers the advantage of shared resources, coordinated discovery, and experienced lead counsel. But individual cases within an MDL can still vary dramatically in value depending on the severity of the plaintiff’s diagnosis, whether the cancer was caught early or late, and the strength of the causal link between the specific implant and the disease. Women who developed BIA-ALCL and required chemotherapy or radiation will likely have stronger claims than those who had implants removed prophylactically without a cancer diagnosis.
Settlement Prospects and Why Resolution Remains Uncertain
Despite the growing caseload and approaching trial dates, no settlement has been reached in the Allergan Biocell litigation. Allergan has not yet tendered a formal settlement offer. In-person mediation sessions were scheduled with Judge Welsh in October, November, and December 2025, and the court has directed both parties to continue working in good faith toward resolution. But good faith directives are not the same as settlement pressure, and Allergan appears willing to take at least the first bellwether cases to trial before committing to a payout structure. This is not unusual in large-scale device litigation, but it creates real uncertainty for plaintiffs.
Women waiting for compensation may be managing ongoing medical expenses, dealing with the psychological aftermath of a cancer diagnosis, or facing career disruptions — all without knowing when or whether a settlement will materialize. History suggests that pharmaceutical and device companies tend to settle mass tort cases eventually, particularly when bellwether verdicts go against them. But “eventually” can mean years. There is also a limitation that plaintiffs should be aware of: even if a settlement is eventually reached, individual payouts in mass tort cases are often tiered based on injury severity. Women with confirmed BIA-ALCL diagnoses who required aggressive treatment will likely receive far more than those who had implants removed as a precaution. The structure of any future settlement grid will determine how compensation is distributed, and those details are typically negotiated after the broad terms are agreed upon.
New Research Links BRCA Mutations to Higher BIA-ALCL Risk
A 2025 study published in Blood Advances added a significant new dimension to the textured implant debate. Researchers found that women with BRCA1 or BRCA2 mutations who have textured breast implants develop BIA-ALCL at a rate 16 times higher than non-BRCA carriers with the same implants. This finding is particularly concerning because BRCA-positive women are among the most likely to undergo prophylactic mastectomies followed by breast reconstruction with implants — the exact procedure that could expose them to elevated BIA-ALCL risk.
This research could have implications for the litigation as well. If Allergan was aware of or could have anticipated a genetic subpopulation at heightened risk, plaintiffs’ attorneys may argue that the company’s failure to warn was even more egregious. For women who carry BRCA mutations and currently have textured implants, this study underscores the importance of discussing monitoring options with their oncologists and plastic surgeons.
What Comes Next for Textured Breast Implant Litigation
The next 12 months will be decisive. With bellwether trials scheduled for June and October 2026 and fact discovery wrapping up in early 2026, both sides will soon have to show their hand. The FDA updated its breast implant safety data on February 6, 2025, and continues to track BIA-ALCL reports — as of June 30, 2024, the agency had documented 552 U.S. cases and 16 U.S.
deaths. Those numbers, while small relative to the total number of women with breast implants, represent real people whose lives were disrupted by a risk they were not adequately warned about. Whether the litigation ends in a negotiated settlement, a series of jury verdicts, or some combination of both, the Allergan Biocell case has already changed the landscape of breast implant regulation. The recall prompted many plastic surgeons to move away from textured implants entirely, and it forced a broader conversation about how medical device manufacturers communicate risk. For women still navigating the aftermath — whether they have been diagnosed with BIA-ALCL or are living with the anxiety of an implant they now distrust — the bellwether trials may finally bring some clarity.
Conclusion
The textured breast implant cancer lawsuit against Allergan represents one of the more consequential medical device litigations in recent years. With 1,425 pending cases in the MDL, 86 percent of reported BIA-ALCL cases linked to Allergan’s Biocell implants, and bellwether trials approaching in mid-2026, the litigation is reaching a critical phase. The absence of a settlement offer from Allergan means plaintiffs are preparing for trial, and the outcomes of those first cases will likely determine whether the company comes to the table with meaningful compensation.
Women who received textured breast implants — particularly Allergan Biocell implants — and who have experienced symptoms such as swelling, pain, or fluid collection around the implant should seek medical evaluation and legal consultation. The statute of limitations varies by state, and waiting too long can forfeit the right to file a claim. With new research linking BRCA mutations to dramatically elevated BIA-ALCL risk and the FDA continuing to update its safety data, the medical and legal picture is still evolving. Staying informed and acting promptly are the two most important steps for anyone affected.
Frequently Asked Questions
What is BIA-ALCL and how is it different from breast cancer?
BIA-ALCL is breast implant-associated anaplastic large cell lymphoma, a rare cancer of the immune system — not a form of breast cancer. It develops in the scar tissue and fluid surrounding a breast implant and was officially classified as a distinct disease by the World Health Organization in 2016.
Which breast implants were recalled?
In July 2019, the FDA requested Allergan recall all Biocell textured breast implants and tissue expanders. The recall was specific to Allergan’s Biocell product line, not all textured implants from every manufacturer, though 86 percent of reported BIA-ALCL cases have been associated with Allergan’s textured implants.
Has there been a settlement in the Allergan breast implant lawsuit?
No. As of the latest updates, no settlement has been reached and Allergan has not tendered a formal settlement offer. Mediation sessions were held in late 2025, and the court has directed both parties to continue working toward resolution. The first bellwether trial is set for June 15, 2026.
How long after getting textured implants can BIA-ALCL develop?
The median time from implant placement to BIA-ALCL diagnosis is nine years, but cases have been reported anywhere from one to 22 years after surgery. This long latency period means some women may not yet know they are affected.
What compensation are plaintiffs seeking?
Plaintiffs are claiming damages for costs of diagnosis and treatment, explant surgery, reconstructive surgery, lost wages, pain and suffering, and emotional distress. The central allegation is that Allergan failed to properly warn women and their doctors about the cancer risk associated with textured breast implants.
Are women with BRCA gene mutations at higher risk?
Yes. A 2025 study found that women with BRCA1 or BRCA2 mutations who have textured breast implants develop BIA-ALCL at a rate 16 times higher than non-BRCA carriers. This is particularly significant because BRCA-positive women frequently undergo mastectomies followed by implant-based reconstruction.